ES2168302T3 - Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e. - Google Patents

Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e.

Info

Publication number
ES2168302T3
ES2168302T3 ES94920705T ES94920705T ES2168302T3 ES 2168302 T3 ES2168302 T3 ES 2168302T3 ES 94920705 T ES94920705 T ES 94920705T ES 94920705 T ES94920705 T ES 94920705T ES 2168302 T3 ES2168302 T3 ES 2168302T3
Authority
ES
Spain
Prior art keywords
serotype
botulin toxin
neuromuscular
disorders
states
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94920705T
Other languages
English (en)
Inventor
K Roger Aoki
Michael W Grayston
Steven R Carlson
Judith M Leon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2168302T3 publication Critical patent/ES2168302T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

UN METODO DE TRATAMIENTO DE UN PACIENTE QUE SUFRE DE UNA ENFERMEDAD, DESORDEN O CONDICION INCLUYE LA ADMINISTRACION AL PACIENTE DE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE TOXINA DE BOTULINA DE UN SEROTIPO SELECCIONADO HASTA QUE EL PACIENTE EXPERIMENTE PERDIDA DE RESPUESTA CLINICA A LA TOXINA DE BOTULINA ADMINISTRADA Y POSTERIORMENTE LA ADMINISTRACION AL PACIENTE DE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE OTRA TOXINA DE BOTULINA DE UN SEROTIPO DIFERENTE.
ES94920705T 1993-06-10 1994-06-07 Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e. Expired - Lifetime ES2168302T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7504893A 1993-06-10 1993-06-10

Publications (1)

Publication Number Publication Date
ES2168302T3 true ES2168302T3 (es) 2002-06-16

Family

ID=22123211

Family Applications (5)

Application Number Title Priority Date Filing Date
ES04027109T Expired - Lifetime ES2335662T3 (es) 1993-06-10 1994-06-07 Tratamiento de trastornos y afecciones neuromusculares con diferentes serotipos de botulinum.
ES03018639T Expired - Lifetime ES2329232T3 (es) 1993-06-10 1994-06-07 Tratamiento de trastornos y afecciones neuromusculares con un serotipo botulinico diferente.
ES04027108T Expired - Lifetime ES2335281T3 (es) 1993-06-10 1994-06-07 Tratamiento de trastornos y afecciones neuromusculares con un serotipo botulinico diferente.
ES08002883T Expired - Lifetime ES2341140T3 (es) 1993-06-10 1994-06-07 Tratamiento de trastornos y afecciones neuromusculares con un seropositivo botulinico diferente.
ES94920705T Expired - Lifetime ES2168302T3 (es) 1993-06-10 1994-06-07 Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e.

Family Applications Before (4)

Application Number Title Priority Date Filing Date
ES04027109T Expired - Lifetime ES2335662T3 (es) 1993-06-10 1994-06-07 Tratamiento de trastornos y afecciones neuromusculares con diferentes serotipos de botulinum.
ES03018639T Expired - Lifetime ES2329232T3 (es) 1993-06-10 1994-06-07 Tratamiento de trastornos y afecciones neuromusculares con un serotipo botulinico diferente.
ES04027108T Expired - Lifetime ES2335281T3 (es) 1993-06-10 1994-06-07 Tratamiento de trastornos y afecciones neuromusculares con un serotipo botulinico diferente.
ES08002883T Expired - Lifetime ES2341140T3 (es) 1993-06-10 1994-06-07 Tratamiento de trastornos y afecciones neuromusculares con un seropositivo botulinico diferente.

Country Status (8)

Country Link
US (3) US6872397B2 (es)
EP (7) EP1099445A3 (es)
JP (4) JPH08511536A (es)
AU (1) AU689115B2 (es)
CA (3) CA2332406C (es)
DE (6) DE69435254D1 (es)
ES (5) ES2335662T3 (es)
WO (1) WO1994028922A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
CA2138020C (en) * 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
EP1099445A3 (en) * 1993-06-10 2001-09-05 Allergan, Inc. Treatment of neuromuscular disorders and conditions with different botulinum serotype
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US20040126396A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
ES2332905T3 (es) * 1993-12-28 2010-02-15 Allergan, Inc. Uso del componente neurotoxico de la toxina botulinica para el tratamiento de trastornos de musculos lisos.
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
DE69627963T2 (de) * 1995-06-06 2004-03-04 Pearce, L. Bruce, Cambridge Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen
AU2340299A (en) 1998-01-26 1999-08-09 University Of Massachusetts Biologically active hemagglutinin from type a (clostridium botulinum) and methods of use
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
AU2003272800A1 (en) * 2002-10-01 2004-04-23 University Of Maryland Methods for identifying inhibitors of botulinum neurotoxins
AU2004216901B2 (en) * 2003-03-06 2009-11-12 Botulinum Toxin Research Associates, Inc. Treatment of chronic chalazion and hordeolum with botulinum toxin
US20040226556A1 (en) * 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US20080274480A1 (en) * 2004-08-04 2008-11-06 Allergan, Inc. Botulinum Toxin Type a Immunoresistant Assay
EP1982997B1 (en) 2004-09-01 2012-08-08 Allergan, Inc. Degradable clostridial toxins
EP1871789B1 (en) 2005-03-15 2013-11-06 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
ES2351942T3 (es) 2005-04-05 2011-02-14 Allergan Inc Analisis de la actividad de una toxina clostridial.
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US7655243B2 (en) 2005-07-22 2010-02-02 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
JP5826450B2 (ja) 2005-07-22 2015-12-02 ザ ファウンドリー， エルエルシー 治療薬の送達のためのシステムおよび方法
US12433837B2 (en) 2005-07-22 2025-10-07 The Foundry, Llc Systems and methods for delivery of a therapeutic agent
WO2009139739A1 (en) * 2006-02-14 2009-11-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion
WO2007106115A1 (en) 2006-03-14 2007-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
WO2009123174A1 (ja) * 2008-03-31 2009-10-08 財団法人化学及血清療法研究所 A2型ボツリヌス神経毒素製剤
US8088127B2 (en) 2008-05-09 2012-01-03 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
AU2010315396B2 (en) 2009-10-27 2016-05-05 Nuvaira, Inc Delivery devices with coolable energy emitting assemblies
JP6000851B2 (ja) 2009-11-11 2016-10-05 ホライラ， インコーポレイテッド 組織治療および狭窄制御のためのシステム、装置、および方法
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2836193B1 (en) 2012-04-13 2018-01-31 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (ii)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
CN107108703B (zh) 2015-01-09 2022-09-23 益普生生物创新有限公司 阳离子神经毒素
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
WO2018060351A1 (en) 2016-09-29 2018-04-05 Ipsen Biopharm Limited Hybrid neurotoxins
WO2019162696A1 (en) 2018-02-26 2019-08-29 Ipsen Biopharm Limited Use of ultrasound to guide injection of non-cytotoxic protease
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2373454A (en) * 1943-07-09 1945-04-10 Squibb & Sons Inc Method of preparing tetanus toxin
US2719102A (en) * 1949-10-28 1955-09-27 Corn States Serum Company Clostridium perfringens toxoid and process of making the same
US3132995A (en) * 1961-10-20 1964-05-12 Carter Prod Inc Endotoxin fractions and method for producing same
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5055291A (en) * 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US4932936A (en) * 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
US5183462A (en) 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5401243A (en) 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
FR2692475B1 (fr) 1992-06-19 2000-04-21 Montpellier Chirurgie Prothese totale du genou.
CA2138020C (en) 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
EP1099445A3 (en) * 1993-06-10 2001-09-05 Allergan, Inc. Treatment of neuromuscular disorders and conditions with different botulinum serotype
ES2332905T3 (es) 1993-12-28 2010-02-15 Allergan, Inc. Uso del componente neurotoxico de la toxina botulinica para el tratamiento de trastornos de musculos lisos.

Also Published As

Publication number Publication date
EP1374886A3 (en) 2004-02-11
EP1512411B1 (en) 2009-11-18
WO1994028922A1 (en) 1994-12-22
CA2332406C (en) 2005-01-04
JP2005281317A (ja) 2005-10-13
EP1508336B1 (en) 2009-11-18
EP1941898B1 (en) 2010-03-17
DE69435253D1 (de) 2009-12-31
DE69435284D1 (de) 2010-04-29
DE69435254D1 (de) 2009-12-31
EP1941898A2 (en) 2008-07-09
EP1508336A1 (en) 2005-02-23
DE69435235D1 (de) 2009-10-15
ES2341140T3 (es) 2010-06-15
DE122009000066I1 (de) 2010-02-04
US20050129716A1 (en) 2005-06-16
EP0702561A1 (en) 1996-03-27
JP2010111703A (ja) 2010-05-20
US20010012833A1 (en) 2001-08-09
EP1512411A1 (en) 2005-03-09
EP0702561B1 (en) 2002-01-09
EP1166793A1 (en) 2002-01-02
DE69429619T2 (de) 2002-09-12
DE69429619D1 (de) 2002-02-14
US20020010138A1 (en) 2002-01-24
DE122009000066I2 (de) 2010-12-30
CA2164866C (en) 2001-09-11
ES2335281T3 (es) 2010-03-24
HK1061648A1 (en) 2004-09-30
EP1099445A2 (en) 2001-05-16
US6872397B2 (en) 2005-03-29
CA2332406A1 (en) 1994-12-22
EP1374886B1 (en) 2009-09-02
ES2329232T3 (es) 2009-11-24
AU7087894A (en) 1995-01-03
ES2335662T3 (es) 2010-03-31
EP1099445A3 (en) 2001-09-05
JP2011256193A (ja) 2011-12-22
EP1941898A3 (en) 2008-11-05
CA2310845A1 (en) 1994-12-22
CA2164866A1 (en) 1994-12-22
CA2310845C (en) 2001-05-15
JPH08511536A (ja) 1996-12-03
AU689115B2 (en) 1998-03-26
EP1374886A2 (en) 2004-01-02

Similar Documents

Publication Publication Date Title
ES2168302T3 (es) Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e.
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
PT646012E (pt) Cura de feridas e tratamento de perturbacoes fibroticas por tgfbeta-3
IL99699A0 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
EP0850648A3 (en) Combination of thrombolytically active proteins and anticoagulants and uses thereof
WO1994028922B1 (en) Treatment of neuromuscular disorders and conditions with different botulinum serotype
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
ES2166111T3 (es) Uso de tiagabina para el tratamiento de trastornos del sueño.
RU95106651A (ru) Аналоги дзе-тур динорфина и способ лечения толерантных состояний у пациента
PT998287E (pt) Utilizacao de levobupivacaina
WO1999033475A8 (en) Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications
HRP920834B1 (en) A method for producing an administration and/or dosage form for pharmaceutical active substances using a printing method
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
FI942660L (fi) Actinoplanes sp:stä olevia lipopeptidejä, joilla on farmakologista vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
CA2120062A1 (en) Use of Sulodexide and of Medicines Containing It in the Treatment of Diabetic Nephropathy
PT862454E (pt) Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
FI950649L (fi) Substituoidut sykloheksanoliesterit, niiden käyttö sairauksien hoitamiseksi ja farmaseuttiset valmisteet
SE9101341D0 (sv) New medicinal use
UA10335A (uk) Спосіб корекції порушеhь обміhу кальцію у хворих hа сиhдром рейтера хламідійhої етіології
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
UA12425A (uk) Спосіб лікуваhhя субарахhоідальhих крововиливів
UA10259A (uk) Протинабряковий лікарський препарат "нейрополіосм"
RU95111889A (ru) Способ местной анестезии в отиатрии

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 702561

Country of ref document: ES